CPR has built up integrated capabilities from early-stage drug discovery to clinical development. We plan to increase our presence in the region and welcome opportunities to collaborate with synergistic partners in developing targeted treatment solutions.
Strong global network
As a subsidiary of Chugai Pharmaceutical, we are able to strengthen R&D collaborations.
World-class drug discovery by utilizing antibody and cyclic peptide technologies
With our world-leading proprietary antibody engineering and cyclic peptide technology platform, we have built robust capabilities in drug discovery and development including target assessment, lead identification, optimisation, translational pharmacology and the development of new technologies. We aim to create effective therapeutics that can provide lasting benefits for patients.
Access to a vibrant R&D community
Our location amidst global scientific community in the heart of Singapore’s R&D hub augments our ability to carry out world-class drug discovery.
Deep talent pool
We have a highly-experienced team of scientists with strong drug discovery capabilities across the entire spectrum of the drug discovery process.
Our research is aimed at designing therapeutics and advancing treatments that can address patients’ unique needs.
Chugai – A*STAR Joint Development Project for Anti-Dengue Virus Antibody Selected as Grant Recipient by the GHIT Fund
Chugai and A*STAR Begin Joint Research on a Therapeutic Antibody to Fight COVID-19
For collaboration opportunities, please contact us at: email@example.com